Launch of Phase 3 clinical trial with Nefecon in Japan

Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan - Calliditas Therapeutics AB

*Japan Intractable Disease Information Center

CONTACT: 
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: [email protected]

The information was sent for publication, through the agency of the contact persons set out above, on July 4, 2024 at 08:30 a.m. CET.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/calliditas-therapeutics/r/launch-of-phase-3-clinical-trial-with-nefecon-in-japan,c4011121

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/launch-of-phase-3-clinical-trial-with-nefecon-in-japan-302189479.html